The vaccines division of sanofi-aventis Group, Sanofi Pasteur, has filed the first centralized marketing authorization application with the European Medicines Agency (EMEA) for the influenza vaccine delivered by an intradermal (ID) microinjection system. ID delivery is an improvement over intramuscular (IM) injection in terms of enhancing the immune response in the elderly. The vaccine uses BD Soluviaä, which is a microinjection system developed by Becton, Dickinson and Company.